Suppr超能文献

过敏性鼻炎的一种治疗方法:左西替利嗪作用之观点

A treatment for allergic rhinitis: a view on the role of levocetirizine.

作者信息

Holgate Stephen, Powell Richard, Jenkins Maureen, Ali Omar

机构信息

Southampton General Hospital, and University of Southampton, Southampton, UK.

出版信息

Curr Med Res Opin. 2005 Jul;21(7):1099-106. doi: 10.1185/030079905X53298.

Abstract

BACKGROUND

Allergic rhinitis is a significant public health concern in many developed countries. However, despite evidence for a significant impact on patients' quality of life (QoL) including sleep disruption and reduced daytime performance, allergic rhinitis remains under-managed and hence poorly controlled. This is largely owing to lack of knowledge about, and poor adherence to, established treatment guidelines.

SCOPE

The panel considered available evidence and focused on four published studies on the second-generation antihistamine, levocetirizine. Three of these studies explored the clinical impact of levocetirizine in a broad range of different clinical settings.

FINDINGS

Levocetirizine demonstrated an increased benefit over other antihistamines in terms of a more durable antihistamine response: levocetirizine provided improved symptom relief at 24 hours compared to desloratadine or fexofenadine, two frequently prescribed second-generation antihistamines. Levocetirizine also maintained relief of the key symptoms of allergic rhinitis and improved patients' QoL over a treatment period of 6 months, in a real-life setting. The variable efficacy and durability of response of different antihistamines arise from differing modulatory effects on the H(1)-receptor. The speed of relief of symptoms with levocetirizine is supported by the pharmacokinetic data, which shows that steady state plasma concentrations are achieved in a shorter period of time than other second-generation histamines (additionally levocetirizine T(max) is reached in 0.9 h).

CONCLUSION

These findings support both the short-term and long-term use of levocetirizine in the clinical management of allergic rhinitis. The World Health Organization (WHO) ARIA Guidelines (Allergic Rhinitis and its Impact on Asthma), recommend using a combination of a non-sedating antihistamine with a decongestant, or glucocorticosteroids for treating allergic rhinitis - with the order and combination of treatment depending on severity and duration of symptoms.

摘要

背景

在许多发达国家,过敏性鼻炎是一个重大的公共卫生问题。然而,尽管有证据表明其对患者生活质量(QoL)有重大影响,包括睡眠中断和白天表现下降,但过敏性鼻炎的管理仍然不足,因此控制不佳。这主要是由于对既定治疗指南缺乏了解以及依从性差。

范围

该小组审议了现有证据,并重点关注了四项关于第二代抗组胺药左西替利嗪的已发表研究。其中三项研究探讨了左西替利嗪在广泛不同临床环境中的临床影响。

研究结果

与其他抗组胺药相比,左西替利嗪在更持久的抗组胺反应方面显示出更大的益处:与地氯雷他定或非索非那定这两种常用的第二代抗组胺药相比,左西替利嗪在24小时时能更好地缓解症状。在现实生活环境中,左西替利嗪在6个月的治疗期内还能持续缓解过敏性鼻炎的关键症状并改善患者的生活质量。不同抗组胺药反应的疗效和持久性差异源于对H(1)受体的不同调节作用。左西替利嗪缓解症状的速度得到了药代动力学数据的支持,该数据表明,与其他第二代组胺药相比,左西替利嗪能在更短的时间内达到稳态血浆浓度(此外,左西替利嗪在0.9小时内达到T(max))。

结论

这些发现支持左西替利嗪在过敏性鼻炎临床管理中的短期和长期使用。世界卫生组织(WHO)的ARIA指南(过敏性鼻炎及其对哮喘的影响)建议使用非镇静性抗组胺药与减充血剂或糖皮质激素联合治疗过敏性鼻炎——治疗的顺序和组合取决于症状的严重程度和持续时间。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验